Investigational drug · Phase 2
RO7269162
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "RO7269162"
First trial start
2024
May 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RO7269162", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer's Disease
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "RO7269162" as an intervention, largest first.
- A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06402838 · 256 participants · Start May 2, 2024 · Primary completion Nov 19, 2026
Drug: RO7269162; Placebo · For: Alzheimer's Disease
Sites: Santiago, Chile; Aarhus N, Denmark; Koebenhavn Oe, Denmark · 45 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06733298 · 8 participants · Start Jan 8, 2025 · Primary completion Jan 29, 2025
Drug: [ 14C]-labeled RO7269162 · For: Healthy Volunteers
Sites: Groningen, Netherlands
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Alzheimer's Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- TrontinemabRO7126209, RG6102Phase 34 trials
Roche (Genentech) · Alzheimers Disease, Alzheimer's Disease
- [18F]-APN-1607Phase 32 trials
JYAMS PET Research & Development Limited · Alzheimer's Disease, Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
- RemternetugLY3372993Phase 31 trial
Eli Lilly · Alzheimer's Disease
- RO7568282Phase 22 trials
Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease
- VHB937Phase 22 trials
Novartis · Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease
- ABBV-1758Phase 21 trial
AbbVie · Alzheimer's Disease
- E2814Phase 21 trial
Eisai · Alzheimer's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.